Eden Biodesign and Borean Pharma ApS sign deal to develop novel therapeutic candidate for the treatment of cancer

12-Sep-2007

Eden Biodesign Ltd and Borean Pharma ApS announced that they have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies. The project is expected to complete early in 2008.

MBP-DC-SIGN is one of Borean's products to be based on the Mannose-Binding protein (MBP) platform. The MBP platform is delivering a series of highly potent therapeutics for the treatment of cancers, and is the only scaffold that can induce complement-induced lysis.

The agreement with Borean Pharma is the fourth contract to be announced by Eden Biodesign in the past 7 weeks, following announcements for cGMP manufacturing and development projects with CRUK, University of Birmingham and UMIP.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance